- Home
- SDHY vs LRMR Comparison
SDHY vs LRMR Comparison
Compare SDHY & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHY
- LRMR
- Stock Information
- Founded
- SDHY 2020
- LRMR N/A
- Country
- SDHY United States
- LRMR United States
- Employees
- SDHY N/A
- LRMR N/A
- Industry
- SDHY Finance/Investors Services
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- SDHY Finance
- LRMR Health Care
- Exchange
- SDHY Nasdaq
- LRMR Nasdaq
- Market Cap
- SDHY 402.7M
- LRMR 426.9M
- IPO Year
- SDHY N/A
- LRMR N/A
- Fundamental
- Price
- SDHY $16.41
- LRMR $3.34
- Analyst Decision
- SDHY
- LRMR Strong Buy
- Analyst Count
- SDHY 0
- LRMR 8
- Target Price
- SDHY N/A
- LRMR $19.63
- AVG Volume (30 Days)
- SDHY 94.0K
- LRMR 678.8K
- Earning Date
- SDHY 01-01-0001
- LRMR 03-13-2025
- Dividend Yield
- SDHY 8.46%
- LRMR N/A
- EPS Growth
- SDHY N/A
- LRMR N/A
- EPS
- SDHY 1.07
- LRMR N/A
- Revenue
- SDHY N/A
- LRMR N/A
- Revenue This Year
- SDHY N/A
- LRMR N/A
- Revenue Next Year
- SDHY N/A
- LRMR N/A
- P/E Ratio
- SDHY $14.31
- LRMR N/A
- Revenue Growth
- SDHY N/A
- LRMR N/A
- 52 Week Low
- SDHY $13.93
- LRMR $3.01
- 52 Week High
- SDHY $15.50
- LRMR $13.68
- Technical
- Relative Strength Index (RSI)
- SDHY 56.32
- LRMR 29.00
- Support Level
- SDHY $16.06
- LRMR $3.24
- Resistance Level
- SDHY $16.28
- LRMR $3.54
- Average True Range (ATR)
- SDHY 0.11
- LRMR 0.22
- MACD
- SDHY 0.03
- LRMR 0.03
- Stochastic Oscillator
- SDHY 90.12
- LRMR 12.26
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.